Can compounds found in everyday soy-based foods help alleviate COPD symptoms? A new study reveals how diet, particularly isoflavones, plays a role in shaping respiratory health and disease burden in ex-smokers.
Research: Isoflavone intake is associated with reduced incidence of chronic obstructive pulmonary disease. Image credit: Makistock/Shutterstock.com
In recent research, Chronic obstructive pulmonary disease We evaluated whether increased dietary isoflavone intake was associated with improvement in respiratory disease in ex-smokers with chronic obstructive pulmonary disease (COPD).
Dietary patterns and their impact on COPD risk and progression
COPD is a progressive lung disease characterized by persistent airflow obstruction and chronic respiratory symptoms such as coughing, sputum production, and shortness of breath. It often develops as a result of long-term exposure to harmful particles or gases, most commonly tobacco smoke. COPD can cause a significant decline in lung function and quality of life over time.
In addition to exposure to poor air quality and smoking, diet and nutrition are increasingly recognized as factors that can influence the risk of developing COPD. Western dietary patterns, including high intakes of refined grains, red and processed meats, fried foods, and sugary drinks, tend to be associated with increased risk of COPD, increased respiratory symptoms, and decreased lung function. In contrast, a Mediterranean or prudent diet rich in vegetables, fruits, fish, poultry, and whole grains appears to reduce the risk of COPD.
Higher intake of omega-3 fatty acids has been shown to lead to less exacerbation and milder symptoms of COPD. Similarly, isoflavones, compounds found in soy-based foods, may provide benefits by reducing inflammation and platelet activation, both of which are important in COPD and other chronic diseases. However, the specific effects of isoflavones on COPD outcomes include: It is still unclear and requires further research.
Evaluation of the association between isoflavone intake and COPD morbidity
The current study examined the association between isoflavone intake and COPD prevalence among urban participants in the CURE COPD study, which investigated the effects of air pollution and diet on low-income COPD patients in Baltimore, Maryland.
Eligible participants were 40 years of age or older, had physician-diagnosed moderate to severe COPD by spirometry, smoked for 10 pack years or more, and were of low socioeconomic status. Selected participants visited the clinic at baseline, 3 months, and 6 months, had monthly telephone interviews for an additional 6 months, and were followed up for an additional 3 months.
Demographic data and neighborhood characteristics were collected at baseline. Neighborhood poverty rate was defined as the percentage of census-eligible households living below the federal poverty line.
Dietary intake was measured using the Harvard Food Frequency Questionnaire (FFQ) during three visits. Trained staff assessed respiratory symptoms at each clinic. Medication use was self-reported. Health, symptoms, and quality of life were assessed using validated questionnaires. A higher score means a greater impact on COPD. Serum, plasma, and urine samples were collected at each visit.
Isoflavone intake is associated with improvement of respiratory disease and reduction of platelet activation in COPD
The study cohort included 99 participants with complete dietary, biomarker, and respiratory outcome data. The average age of participants was 66.4 years. 55% identified as female and 41% as white. The mean smoking history in this cohort was 46.3 pack-years, and the predicted mean forced expiratory volume per second (FEV1) percent was 49.8%, reflecting substantial airflow limitation consistent with moderate to severe COPD. Most participants reported an annual income of less than $30,000, and nearly half had an education below high school.
The mean isoflavone intake of the study cohort was 1.8 mg, with a median of 1.0 mg. Higher intake was associated with higher educational attainment and higher caloric intake, while other demographics were similar across groups.
After adjusting for key covariates, increased total isoflavone intake was associated with improved respiratory outcomes, with each standard deviation (SD) increase associated with lower COPD Assessment Test (CAT), COPD Clinical Questionnaire (CCQ), and Evaluation of Respiratory Symptoms in COPD (ECSC) scores. The trend toward improved St. George’s Respiratory Questionnaire (SGRQ) scores was not statistically significant. However, the improvement on the CAT reached a minimal clinically important difference, but not on the CCQ.
Isoflavone intake was not significantly associated with dyspnea, exacerbation rates, or biomarkers of inflammation or oxidative stress. In contrast, increased isoflavone consumption was correlated with a 7.4% decrease in urinary 11-dehydrothromboxane B2 (11dTxB2), indicating decreased platelet activation. These results suggest a potential association between isoflavone intake and certain clinical outcomes, with platelet-related pathways being one possible explanation.
Analysis of specific isoflavones showed that higher intakes of daidzein and genistein improved CAT, CCQ, and ECSC scores. Formononetin was associated with lower SGRQ and CAT scores, and glycitein was associated with lower ECSC scores. All showed a trend toward lower urinary thromboxane, with only genistein reaching statistical significance. Biochanin A showed no significant association.
Sensitivity analyzes showed that the association between increased isoflavone intake and improved respiratory disease persisted after adjusting for omega-3 fatty acids. This effect was strongest for CAT and SGRQ scores in individuals with lower omega-3 (eicosapentaenoic and docosahexaenoic acid) intakes, suggesting that isoflavone-related benefits may be more pronounced in individuals with lower overall diet quality.
Sensitivity analyzes adjusting for antiplatelet drug use confirmed an association between increased isoflavone intake and decreased respiratory disease. However, when omega-3 intake and antiplatelet use were taken into account, the association with lower 11dTxB2 decreased and became no longer statistically significant, although the effect size remained similar.
conclusion
A current study of former smokers with COPD in metropolitan Baltimore, Maryland, found that higher intakes of isoflavones were significantly associated with improved respiratory outcomes. Participants with higher intakes of isoflavones reported better health and fewer cough symptoms, with evidence of lower systemic platelet activation. These results indicate that dietary isoflavones may be associated with reduced COPD morbidity, with platelet-related pathways as one possible contributing mechanism.
However, due to the study’s observational design, relatively small sample size, reliance on self-reported dietary data, and limitations of biomarker analysis, these findings must be interpreted with caution and a causal relationship cannot be established.
Click here to download your PDF copy.
